An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies.
about
Essential Medicines List Implementation Dynamics: A Case Study Using Brazilian Federal Medicines Expenditures.Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits.Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab.Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars.Whole genome analysis on the genetic backgrounds associated with the secondary failure to etanercept in patients with rheumatoid arthritis.
P2860
An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
An examination of the mechanis ...... in inflammatory arthropathies.
@en
An examination of the mechanis ...... in inflammatory arthropathies.
@nl
type
label
An examination of the mechanis ...... in inflammatory arthropathies.
@en
An examination of the mechanis ...... in inflammatory arthropathies.
@nl
prefLabel
An examination of the mechanis ...... in inflammatory arthropathies.
@en
An examination of the mechanis ...... in inflammatory arthropathies.
@nl
P2093
P1476
An examination of the mechanis ...... in inflammatory arthropathies.
@en
P2093
Antonio García-Sánchez
Enrique Raya-Álvarez
Francisco Vives
Juan Salvatierra
Mar López-Sidro
Raquel Durán
Sara Bandrés Ciga
P304
P356
10.1097/RHU.0000000000000229
P577
2015-04-01T00:00:00Z